Podcast Episodes

Back to Search
Pharmaceutical Executive Daily: CSL & Alentis Enter $1.6 Billion Global Partnership
Pharmaceutical Executive Daily: CSL & Alentis Enter $1.6 Billion Global Partnership

Jewel Jones warns that pharma catches patient disengagement too late, CSL and Alentis Therapeutics join Jiangsu Nhwa and Somnivera in a day of new li…

1 month, 1 week ago

Short Long
View Episode
Pharmaceutical Executive Daily: Foghorn Therapeutics & Eli Lilly Discontinue Development of FHD-909

Foghorn Therapeutics and Eli Lilly discontinue their SMARCA2 degrader program, Novartis licenses Abogen's autoimmune mRNA therapy while AstraZeneca, …

1 month, 2 weeks ago

Short Long
View Episode
Pharmaceutical Executive Daily: FDA Approves Expanded Indication for Camzyos
Pharmaceutical Executive Daily: FDA Approves Expanded Indication for Camzyos

Regeneron and Sanofi expand their antibody alliance with four new drug candidates, FDA approves Camzyos for adolescents with obstructive hypertrophic…

1 month, 2 weeks ago

Short Long
View Episode
Pharmaceutical Executive Daily: Peptide Ruling Stalls
Pharmaceutical Executive Daily: Peptide Ruling Stalls

Novo Nordisk data show real-world weight loss after switching to its oral semaglutide pill, FDA's peptide rulemaking stalls while its enforcement arm…

1 month, 2 weeks ago

Short Long
View Episode
A Leadership Call to Action for Biotech
A Leadership Call to Action for Biotech


In this episode of Leading Edge with Ken Banta, Jeremy Levin, D.Phil, MB BChir, co-founder and executive chairman of Ovid Therapeutics, joins Banta,…

1 month, 2 weeks ago

Short Long
View Episode
Pharmaceutical Executive Daily: Fabrice Chouraqui Steps Down as CEO of Pharming
Pharmaceutical Executive Daily: Fabrice Chouraqui Steps Down as CEO of Pharming

New U.S. guidance carves out tariff exemptions for specialty pharmaceuticals, Pharming's Fabrice Chouraqui steps down as CEO amid a board rift, and a…

1 month, 2 weeks ago

Short Long
View Episode
Pharmaceutical Executive Daily: Merck Acquires SPR2015 in $2.13 Billion Licensing Deal
Pharmaceutical Executive Daily: Merck Acquires SPR2015 in $2.13 Billion Licensing Deal

Merck licenses a preclinical KRAS G12D inhibitor from SciBrunch, FDA approves Olumiant, Juvmo, and Atebrioz across three separate indications, and Ma…

1 month, 3 weeks ago

Short Long
View Episode
Pharmaceutical Executive Daily: FDA Approves Welireg Plus Lenvima
Pharmaceutical Executive Daily: FDA Approves Welireg Plus Lenvima

FDA approves Merck and Eisai's Welireg-Lenvima combination for advanced kidney cancer, a platform-deal roundup covers Novo Nordisk, Genentech, and Ro…

1 month, 3 weeks ago

Short Long
View Episode
Pharmaceutical Executive Daily: FDA Approves Onswik
Pharmaceutical Executive Daily: FDA Approves Onswik

InnoCare Pharma and Eli Lilly ink a multibillion-dollar research collaboration, FDA approves Lilly's once-weekly insulin Onswik for type 2 diabetes, …

1 month, 3 weeks ago

Short Long
View Episode
Pharmaceutical Executive Daily: Mike Doustdar Open to Direct Listing for Novo Shares
Pharmaceutical Executive Daily: Mike Doustdar Open to Direct Listing for Novo Shares

EVERSANA's Jen Norton talks about how AI is reshaping market access strategy, a new analysis from MIT and Harvard Business School names clinical data…

1 month, 3 weeks ago

Short Long
View Episode

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us